Ritter Pharmaceuticals Reports Fourth Quarter and Full Year

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update

LOS ANGELES, CA--(Marketwired - Mar 21, 2016) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a leading developer of novel therapeutics that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results and a business update for the fourth quarter and full year ended December 31, 2015.

2015 and Recent Operational Highlights

  • Initiated Phase 2b/3 clinical trial of lead product candidate, RP-G28 in patients with lactose intolerance
  • Entered into a $10 million common stock purchase agreement with Aspire Capital Fund
  • Closed initial public offering in June 2015, generating gross proceeds of $20 million
  • Bolstered leadership team with appointment of AnnKatrin Petersen-Jappelli, M.D., M.SC. as Chief Medical Officer and addition of William J. Sandborn, M.D. to Medical Advisory Board
  • Strengthened intellectual property portfolio with patents covering manufacturing process for RP-G28 and composition for ameliorating symptoms of lactose intolerance, respectively

"2015 was a significant year for Ritter Pharmaceuticals with financing and building activities preparing us for the first quarter 2016 commencement of our Phase 2b/3 trial of RP-G28 and dosing of our first patient today, March 21, 2016. With 6 trial sites currently screening subjects, we expect to have 20 sites recruiting by mid-year, and are on-track to report top-line data in early 2017. We have effectively utilized our assets to reach this important milestone, and have further established a solid foundation for long-term growth and success by strengthening our executive and advisory teams with key appointments, as well as adding important patents to our portfolio," said Michael D. Step, Chief Executive Officer of Ritter Pharmaceuticals.

Andrew Ritter, President of Ritter Pharmaceuticals, added, "RP-G28 has the potential to become the first FDA approved product to treat lactose intolerance. This therapeutic represents a possible breakthrough in the treatment of lactose intolerance and a viable alternative to lactase supplements. We are proud of the progress we have made and look forward to updating our shareholders as we continue to advance our Phase 2b/3 clinical trial."

Fourth Quarter and Full Year 2015 Financial Results

For the fourth quarter of 2015, Ritter Pharmaceuticals reported a net loss attributable to common stockholders of approximately $2.2 million compared to a net loss of approximately $1.7 million for the fourth quarter of 2014. Basic and diluted net loss per share was $0.27 for the three months ended December 31, 2015 compared to basic and diluted net loss per share of $3.70 for the same period in 2014.

For the year ended December 31, 2015, Ritter Pharmaceuticals reported a net loss attributable to common stockholders of approximately $9.2 million compared to a net loss of approximately $3.1 million for the year ended December 31, 2014. Basic and diluted net loss per share was approximately $3.11 for the year ended December 31, 2015 compared to basic and diluted net loss per share of approximately $6.79 for the same period in 2014.

Research and development expenses for the fourth quarter of 2015 totaled approximately $676,000 compared to approximately $45,000 for the fourth quarter of 2014. This increase was due to the initiation of the Phase 2b/3 clinical trial.

For the year ended December 31, 2015, research and development expenses totaled approximately $2.3 million compared to approximately $114,000 for the year ended December 31, 2014. This increase in research and development expenses was primarily attributable to increased manufacturing costs associated with the preparation of product for clinical trial.

General and administrative expenses for the fourth quarter of 2015 were approximately $1.5 million, compared to approximately $1.2 million for the fourth quarter of 2014. This increase was primarily due an increase in costs of being a public company and the appointment and hiring of key personnel during this period.

For the year ended December 31, 2015, general and administrative expenses were approximately $6.4 million, compared to approximately $2.0 million for the year ended December 31, 2014. The increase in general and administrative expenses was primarily due to an increase in stock based compensation expenses, increased headcount, and costs associated with the closing of the Company's initial public offering.

Total operating expenses for the fourth quarter of 2015 were approximately $2.3 million compared to approximately $1.4 million for the fourth quarter of 2014.

For the year ended December 31, 2015, total operating expenses were $8.9 million, compared to approximately $2.3 million for the year ended December 31, 2014.

As of December 31, 2015, Ritter Pharmaceuticals had cash and cash equivalents of approximately $15.8 million.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company is advancing human gut health research by exploring the metabolic capacity of gut microbiota, and translating the functionality of these microbiome modulators into safe and effective applications. Their lead drug candidate, RP-G28, has the potential to become the first FDA-approved drug for lactose intolerance, a condition that affects more than one billion people worldwide.

Forward-Looking Statements

This release may contain forward-looking statements, which express the current beliefs and expectations of Ritter Pharmaceuticals' management. Such statements involve a number of known and unknown risks and uncertainties that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Any statements contained herein that do not describe historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts Investor Contact: David Burke dburke@theruthgroup.com (646) 536-7009

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 127

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 5

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 271

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 13

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 71

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 30

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 292

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
Skanska Adds $80M U.S. Tech Facility Contract to Orders

Updated Category News Views 107

An $80 million add-on is the sort of construction news that looks modest until you remember what it says about the customer relationship. Skanska has won an additional contract from an existing client for a U.S. tech facility, worth roughly SEK 760 million, and it will enter U.S. order bookings in the fourth quarter of 2026. No fireworks, no grand strategic...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 165

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 107

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading

Top 5 Most Recently Viewed Articles

Prinses Máxima Center Enhances Genomics with Callisto™ Innovation

Updated Category News Views 300

Prinses Máxima Center's Partnership with Volta Labs The Prinses Máxima Center for Pediatric Oncology is making headlines with its recent acquisition of the Callisto™ platform from Volta Labs. This major step forward aims to enhance efficiency in sample preparation across a variety of genomics workflows, specifically designed for both Illumina and Oxford Nanopore...

Continue Reading
Keros Therapeutics to Showcase Innovations at Key Conferences

Updated Category News Views 152

Exciting Participation of Keros Therapeutics in Major Conferences Keros Therapeutics, Inc. is making significant strides in the biopharmaceutical landscape by focusing on innovative therapies targeting disorders associated with the TGF-ß family of proteins. Recently, the company announced that its Chair and Chief Executive Officer, Jasbir S. Seehra, Ph.D., will represent...

Continue Reading
KULR Technology Unveils Major Licensing Breakthrough with Japan

Updated Category News Views 133

KULR Technology Group, Inc. (NYSE American: KULR) unveiled a major licensing agreement back in 2024 that had traders buzzing. This $2.35 million deal centered around their vibration reduction technology, known as KULR Xero Vibe (KXV). At first glance, it seemed like a solid step for the company into new markets, but let’s peel back the layers and see what's really...

Continue Reading
Mainz Biomed Achieves Significant Milestones and Results

Updated Category News Views 204

Mainz Biomed Reports Financial Results and Strategic Progress Lab network revenue up by 33% year-over-year. Operating loss down by 30% and net loss by 18%. Partnerships driving innovation and growth forward. Highlighting 2025 accomplishments and future goals. Mainz Biomed N.V. (NASDAQ: MYNZ), a pioneering molecular genetics diagnostic firm, has reported its financial...

Continue Reading
PioCreat Launches Innovative Mini Dental 3D Printer During Expo

Updated Category News Views 247

PioCreat Launches Innovative Mini Dental 3D Printer at Moscow Event PioCreat, a well-respected name in the 3D printing sector, made a significant impression at the dental industry's notable event, the 2025 Moscow Dental Expo. This gathering, renowned for showcasing advancements in digital dentistry, took place at Crocus-Expo IEC, attracting a wide array of international...

Continue Reading